American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Complete response to dabrafenib-trametinib combo improves survival outcomes in advanced melanoma

Roshini Claire Anthony, 20190705140303

A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.

Low-dose adjuvant ipilimumab improves OS in high-risk melanoma

Elaine Soliven, 20190628060000

Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.

Neoadjuvant T-DM1 + pertuzumab tied to elevated risk of EFS events in HER2+ breast cancer

Elaine Soliven, 20190618120000

Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.

Pembrolizumab improves survival in untreated metastatic nonsquamous NSCLC

Christina Lau, 20190618074033

Patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) may have their overall survival (OS) and progression-free survival (PFS) approximately doubled with pembrolizumab in combination with platinum-based chemotherapy vs chemotherapy alone, according to updated results of the KEYNOTE-189 trial reported at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial

20190617080425

Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.

Slideshow: Highlights from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

20190617075838

Slideshow: Highlights from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

MONALEESA-7 highlights survival benefit of ribociclib in premenopausal women with HR+ HER2- breast cancer

Roshini Claire Anthony, 20190616090305

The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.

TITAN seals a win for apalutamide + ADT in mCSPC

Pearl Toh, 20190615150000

Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.

Taxane-based TPEx shows promise for head, neck cancer

Audrey Abella, 20190614100000

The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.

Frontline pembrolizumab noninferior to chemo with less toxicity in gastric cancer

Pearl Toh, 20190613190000

Pembrolizumab is noninferior to standard chemotherapy for overall survival (OS) in advanced gastric or gastroesophageal junction (G/GEJ) cancer in the first-line setting, thus providing a potential alternative treatment option for patients with G/GEJ, according to the KEYNOTE-062 study presented at ASCO 2019.